|
Article Cited by others ORIGINAL ARTICLE
Clinical activity of abiraterone plus prednisone in docetaxel-naοve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
Lin Guo-Wen, Li Gao-Xiang, Dai Bo, Ye Ding-Wei, Kong Yun-Yi, Wang Yue, Shen Yi-Jun
Year : 2019| Volume: 21| Issue : 2 | Page no: 131-136 | This article has been cited by | | 1 |
Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy? |
|
| | Ming-kun Chen, Zhi-jian Liang, Dao-Sheng Luo, Kang-yi Xue, De-ying Liao, Zheshen Li, Yuzhong Yu, Zhe-Sheng Chen, Shan-Chao Zhao | | | Frontiers in Pharmacology. 2022; 13 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration-resistant prostate cancer: Real-world experience in the Southeast Asian cohort |
|
| | Jasmine Lim,Akara Amantakul,Nisha Shariff,Bannakij Lojanapiwat,Adlinda Alip,Teng Aik Ong,Shankaran Thevarajah,Firdaus Ahmayuddin,Adeline Mathew,Supon Sriplakich,Jaraspong Vuthiwong,Flora Li Tze Chong,Marniza Saad | | | Cancer Medicine. 2020; | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Separate Chinese lines for prostate cancer? |
|
| | FinnEdler von Eyben | | | Asian Journal of Andrology. 2018; 0(0): 0 | | | [Pubmed] [Google Scholar] [DOI] | |
|
|
|
|
